OpenAI Buys AI Biotech Startup To Help Scientists

OpenAI bought Orchestra Bio to improve Rosalind, its AI platform for life sciences. The deal adds software that helps drug developers organize research, studies, and development work.

Orchestra’s platform uses AI agents to track progress, spot problems, and make it easier for internal teams and outside companies to work together.

OpenAI, the company behind ChatGPT, wants to connect scientific research with the planning and work needed to develop potential new drugs. This could help address a process that can take 10 years or more.

OpenAI also explained how a problem in one part of drug development can cause delays in other parts. For example, a manufacturing failure could delay the start of a clinical trial. Orchestra’s AI agents are designed to show how such problems could affect later steps, gather useful information, and help teams compare possible solutions.

Drug Researchers Turn To AI

Anthropic, a rival to OpenAI, recently reported that its Claude AI model designed 318,000 possible proteins in 64 hours to target toxins in scorpion venom. Seventeen of these designs met the required binding standards in laboratory tests.

However, the experiment did not show whether the proteins could actually neutralize the venom. This highlights the difference between creating promising candidates with AI and developing treatments that work.

These results show that AI companies are competing to speed up drug discovery. At the same time, acquisitions and partnerships are helping them use the technology not just for research, but also for the complicated work of developing and delivering new treatments.

Separately, OpenAI pointed to its work with Novo Nordisk and Moderna as examples of how it can work with drug companies.

“Alongside researchers and our partners, we aim to make more discoveries possible and help new medicines reach patients sooner,” the company wrote.

Photo Courtesy: Evolf on Shutterstock.com